Published in Neurobiol Aging on September 04, 2013
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Mild cognitive impairment: clinical characterization and outcome. Arch Neurol (1999) 33.06
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet (1998) 7.26
Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature (1992) 7.02
ENCODE whole-genome data in the UCSC Genome Browser. Nucleic Acids Res (2009) 5.98
aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell (2002) 4.37
Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem (2004) 4.23
Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA (2003) 4.16
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci U S A (2003) 3.36
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol (2009) 3.34
Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol (2006) 2.79
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol (1998) 2.77
Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol (1995) 2.62
Proteome-based plasma biomarkers for Alzheimer's disease. Brain (2006) 1.98
Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol (2011) 1.83
Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord (2005) 1.82
The behaviour of random forest permutation-based variable importance measures under predictor correlation. BMC Bioinformatics (2010) 1.59
Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol (2008) 1.48
Aβ-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol (2011) 1.42
Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. J Alzheimers Dis (2008) 1.40
Mining biomarkers in human sera using proteomic tools. Proteomics (2004) 1.30
Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. Mol Biosyst (2007) 1.28
Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. FASEB J (2005) 1.26
Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain (2008) 1.20
alpha2-Macroglobulin and haptoglobin suppress amyloid formation by interacting with prefibrillar protein species. J Biol Chem (2008) 1.18
A closer look at alpha-secretase. Curr Alzheimer Res (2008) 1.17
α-2-Macroglobulin: a physiological guardian. J Cell Physiol (2013) 1.13
Part-time alpha-secretases: the functional biology of ADAM 9, 10 and 17. Curr Alzheimer Res (2008) 1.12
Functional gamma-secretase complex assembly in Golgi/trans-Golgi network: interactions among presenilin, nicastrin, Aph1, Pen-2, and gamma-secretase substrates. Neurobiol Dis (2003) 1.11
Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's disease. J Alzheimers Dis (2013) 1.07
An association analysis of Alzheimer disease candidate genes detects an ancestral risk haplotype clade in ACE and putative multilocus association between ACE, A2M, and LRRTM3. Am J Med Genet B Neuropsychiatr Genet (2009) 1.05
Axonal transport of APP and the spatial regulation of APP cleavage and function in neuronal cells. Exp Brain Res (2011) 1.03
The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer's disease-related pathology. Neuropathol Appl Neurobiol (2005) 1.02
Genetic association of Alzheimer's disease with multiple polymorphisms in alpha-2-macroglobulin. Hum Mol Genet (2003) 1.01
Functions of Aβ, sAPPα and sAPPβ : similarities and differences. J Neurochem (2011) 0.99
Genetic association of an alpha2-macroglobulin (Val1000lle) polymorphism and Alzheimer's disease. Hum Mol Genet (1998) 0.99
The upside of APP at synapses. CNS Neurosci Ther (2010) 0.98
Synaptic dysfunction in Alzheimer's disease. Adv Exp Med Biol (2012) 0.94
The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain. Biochem Soc Trans (2007) 0.93
Aβ amyloid, cognition, and APOE genotype in healthy older adults. Alzheimers Dement (2012) 0.92
Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjects. Clin Biochem (2008) 0.92
Acute phase reactant alpha 1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer disease. Alzheimer Dis Assoc Disord (1995) 0.92
The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. Biomarkers (2008) 0.87
Blood-brain barrier damage induces release of alpha2-macroglobulin. Mol Cell Proteomics (2003) 0.87
Extracellular chaperones modulate the effects of Alzheimer's patient cerebrospinal fluid on Abeta(1-42) toxicity and uptake. Cell Stress Chaperones (2009) 0.86
Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum: a role in Alzheimer's disease? J Alzheimers Dis (2012) 0.86
The alpha2-macroglobulin gene in AD: a population-based study and meta-analysis. Neurology (2000) 0.82
Inhibition of beta2-microglobulin amyloid fibril formation by alpha2-macroglobulin. J Biol Chem (2011) 0.82
Acute-phase proteins in Alzheimer's disease. Eur Neurol (1988) 0.81
Genetic association of argyrophilic grain disease with polymorphisms in alpha-2 macroglobulin and low-density lipoprotein receptor-related protein genes. Neuropathol Appl Neurobiol (2002) 0.80
Alpha2-macroglobulin gene and Alzheimer's disease: confirmation of association by haplotypes analyses. Ann Neurol (2000) 0.80
A shift in microglial β-amyloid binding in Alzheimer's disease is associated with cerebral amyloid angiopathy. Brain Pathol (2012) 0.79
Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain. Arch Neurol (1996) 0.79
Candidate genes for late-onset Alzheimer's disease: focus on chromosome 12. Mech Ageing Dev (2005) 0.79
Protease-activated alpha-2-macroglobulin can inhibit amyloid formation via two distinct mechanisms. FEBS Lett (2013) 0.78
Depletion of potential A2M risk haplotype for Alzheimer's disease in long-lived individuals. Eur J Hum Genet (2010) 0.77
A deletion polymorphism in the human alpha-2-macroglobulin (A2M) gene. Nucleic Acids Res (1991) 0.76
Characterization of a novel positive transcription regulatory element that differentially regulates the alpha-2-macroglobulin gene in replicative senescence. Biogerontology (2011) 0.76
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet (2007) 14.05
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord (2006) 8.04
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA (2004) 6.74
The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature (2011) 6.71
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA (2003) 6.34
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
Glucose levels and risk of dementia. N Engl J Med (2013) 4.95
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66
Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol (2007) 4.47
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry (2006) 2.85
A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am J Psychiatry (2013) 2.84
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol (2006) 2.79
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol (2007) 2.72
Independent predictors of cognitive decline in healthy elderly persons. Arch Neurol (2002) 2.70
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry (2003) 2.59
Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol (2006) 2.42
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc (2010) 2.34
Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res (2009) 2.27
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol (2008) 2.25
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology (2012) 2.19
The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol (2010) 2.19
Identification of a novel gene on chromosome 7q11.2 interrupted by a translocation breakpoint in a pair of autistic twins. Genomics (2002) 2.16
GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron (2013) 2.13
Trajectory of mild cognitive impairment onset. J Int Neuropsychol Soc (2008) 2.13
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med (2002) 2.08
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Comprehensive search for Alzheimer disease susceptibility loci in the APOE region. Arch Neurol (2012) 1.97
Unobtrusive assessment of activity patterns associated with mild cognitive impairment. Alzheimers Dement (2008) 1.95
Uric acid as a CNS antioxidant. J Alzheimers Dis (2010) 1.93
Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res (2004) 1.91
Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry (2007) 1.91
Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci U S A (2003) 1.90
Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol (2008) 1.89
Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. Ann Neurol (2007) 1.88
A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. Am J Psychiatry (2003) 1.83
Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis (2006) 1.82
Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord (2005) 1.82
Functional analysis of APOE locus genetic variation implicates regional enhancers in the regulation of both TOMM40 and APOE. J Hum Genet (2011) 1.81
Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol (2008) 1.81
Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol (2007) 1.81
Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol (2002) 1.79
Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association. Genomics (2007) 1.78
Ecology of the aging human brain. Arch Neurol (2011) 1.78
Blood pressure and brain injury in older adults: findings from a community-based autopsy study. J Am Geriatr Soc (2009) 1.76
Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res (2008) 1.74
An electronic pillbox for continuous monitoring of medication adherence. Conf Proc IEEE Eng Med Biol Soc (2006) 1.72